375 related articles for article (PubMed ID: 22237457)
1. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Lee JL; Park I; Park K; Park S; Ahn Y; Ahn JH; Kim TW; Ahn S; Song C; Hong JH; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2012 Apr; 138(4):687-93. PubMed ID: 22237457
[TBL] [Abstract][Full Text] [Related]
2. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Ravaud A; Digue L; Trufflandier N; Smith D
Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
[No Abstract] [Full Text] [Related]
3. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
4. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
6. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
[TBL] [Abstract][Full Text] [Related]
7. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Porta C; Paglino C; Imarisio I; Canipari C; Chen K; Neary M; Duh MS
BMC Cancer; 2011 Mar; 11():105. PubMed ID: 21435216
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
9. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
10. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
11. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Kontovinis L; Laschos K; Karadimou A; Andreadis C; Bamias A; Paraskevopoulos P; Dimopoulos M; Papazisis K
Med Oncol; 2012 Jun; 29(2):750-4. PubMed ID: 21279702
[TBL] [Abstract][Full Text] [Related]
13. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Buchler T; Klapka R; Melichar B; Brabec P; Dusek L; Vyzula R; Abrahamova J
Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
[TBL] [Abstract][Full Text] [Related]
15. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
16. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Masini C; Sabbatini R; Porta C; Procopio G; Di Lorenzo G; Onofri A; Buti S; Iacovelli R; Invernizzi R; Moscetti L; Aste MG; Pagano M; Grosso F; Lucia Manenti A; Ortega C; Cosmai L; Del Giovane C; Conte PF
BJU Int; 2012 Sep; 110(5):692-8. PubMed ID: 22364110
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
18. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
